CK Life Sciences International (Holdings), Inc. (0775) AI Stock Analysis

• Market Cap: HK$9.23B
• Dividend Yield: N/A
• Average Volume (3M): 10.86M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 2.10%
• EPS Growth: -1350.00%
• Country: HK
• Employees: 2,033
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 9,611,072,000
• 10 Day Avg. Volume: 5,935,284
• 30 Day Avg. Volume: 10,857,323
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.00
• Price Target Upside: 4.17% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: HK$1.00 ▲(4.17% Upside)

The stock's overall score is primarily influenced by its financial performance and technical analysis. While the company faces profitability challenges and high leverage, its operational efficiency and positive cash flows provide some strength. The technical indicators show bullish momentum, supporting a higher score. However, the negative P/E ratio and lack of dividend yield weigh down the valuation score, impacting the overall assessment.

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company Description

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines. The company is also involved in the contract manufacturing of complementary healthcare medicines, pharmaceutical products, and cosmetics; licensing of registration activities and the importation of finished agricultural goods; holding of land and buildings; financing activities; investment in financial instruments and vineyards; trading of biotechnology products and nutritional supplements; and manufacturing, wholesaling, retailing, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as turf fertilizers, chemicals, and professional pest products; produces, refines, and distributes salt products; and provides research and development services for biotechnology and life sciences technology products. Further, it researches, develops, manufactures, and commercializes drug products to treat pain and melanoma; supplies raw materials for nutritional health, pharmaceutical, cosmetics, personal care, and food segments; and offers packing and asset management services. CK Life Sciences Int'l., (Holdings) Inc. was founded in 1999 and is headquartered in Tai Po, Hong Kong.

How the Company Makes Money

CK Life Sciences makes money through a diversified revenue model that includes the sale of pharmaceuticals, nutraceuticals, and other health-related products. The company generates revenue from the development and commercialization of proprietary and licensed pharmaceutical products targeting various therapeutic areas. Additionally, its nutraceuticals business, which includes dietary supplements and health products, contributes significantly to its revenue. CK Life Sciences also earns income from its agriculture-related businesses, involving the development and sale of environmentally friendly fertilizers and crop protection products. Strategic partnerships and collaborations with other companies in the biotechnology and healthcare sectors further enhance its revenue streams.

CK Life Sciences International (Holdings), Inc. Financial Statement Overview

Summary

CK Life Sciences is facing profitability challenges with a negative net income in 2024 despite stable revenue growth. Operational efficiency has improved, but high leverage and a declining equity ratio raise financial stability concerns. Positive operating and free cash flows suggest some operational strength, yet the cash flow decline indicates potential cash management issues.

Income Statement

The company has shown a modest revenue growth of 3.75% from 2023 to 2024. However, it reported a negative net income in 2024, resulting in a net profit margin of -2.29%, indicating profitability challenges. The gross profit margin remained stable at 30.64%, and the EBIT margin improved to 14.18%, suggesting operational efficiency improvements despite bottom-line issues.

Balance Sheet

The debt-to-equity ratio increased to 1.74, indicating a higher leverage, which could pose financial risks. The equity ratio decreased to 32.53%, reflecting a lower proportion of equity financing in the asset structure. ROE turned negative due to the net loss, highlighting the strain on shareholder returns.

Cash Flow

Operating cash flow remained positive, although it decreased by 31.23% from the previous year. Free cash flow declined by 30.74%, suggesting reduced excess cash for reinvestment. The free cash flow to net income ratio is not meaningful due to the negative net income, but the company maintained a positive free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.52B	5.32B	5.28B	5.40B	4.94B
Gross Profit	1.69B	1.64B	1.63B	1.63B	1.41B
EBITDA	337.27M	624.75M	469.51M	449.14M	353.62M
Net Income	-126.55M	17.25M	131.96M	162.80M	125.23M
Balance Sheet
Total Assets	10.79B	11.25B	11.27B	11.73B	11.98B
Cash, Cash Equivalents and Short-Term Investments	571.21M	676.16M	704.13M	902.47M	971.71M
Total Debt	6.10B	5.93B	5.95B	6.21B	6.19B
Total Liabilities	7.28B	7.06B	7.11B	7.23B	7.26B
Stockholders Equity	3.51B	4.19B	4.16B	4.50B	4.72B
Cash Flow
Free Cash Flow	154.06M	222.35M	146.69M	206.33M	151.12M
Operating Cash Flow	353.53M	514.18M	363.66M	423.57M	530.96M
Investing Cash Flow	-96.64M	-67.96M	-22.12M	-257.88M	-457.31M
Financing Cash Flow	-341.98M	-477.95M	-515.34M	-220.08M	168.74M

CK Life Sciences International (Holdings), Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Positive. The current price of 0.96 is below the 20-day moving average (MA) of 0.97, above the 50-day MA of 0.92, and above the 200-day MA of 0.66, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 52.11 is Neutral, neither overbought nor oversold. The STOCH value of 16.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0775.

CK Life Sciences International (Holdings), Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	66 Neutral	HK$9.92B	270.86	4.16%	―	34.39%	―
0775	65 Neutral	HK$9.23B	―	-7.26%	―	2.10%	-1350.00%
1672	58 Neutral	HK$14.40B	―	-12.74%	―	-76.58%	-4.90%
1477	54 Neutral	HK$9.31B	―	-7.71%	―	74.73%	31.65%
2142	54 Neutral	HK$10.41B	428.97	2.28%	―	-57.55%	-87.49%
Sector *	51 Neutral	$7.88B	-0.12	-39.83%	2.18%	21.38%	-1.56%
6955	―	HK$10.02B	104.21	4.95%	―	―	―

CK Life Sciences International (Holdings), Inc. Corporate Events

CK Life Sciences Issues Profit Warning Amid Increased R&D Investments

CK Life Sciences International (Holdings) Inc. has issued a profit warning, indicating an expected loss of approximately HK$150 million for the first half of 2025, compared to a HK$1 million profit in the same period in 2024. This shift from profit to loss is primarily due to the company’s strategic decision to increase investments in research and development, while the overall operations remained stable. The final financial results are still being finalized and will be disclosed in the interim results announcement on 12 August 2025.

CK Life Sciences Announces Upcoming Board Meeting for Interim Results

CK Life Sciences International (Holdings) Inc. has announced that its board of directors will meet on August 12, 2025, to approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential returns for shareholders, impacting its market positioning and stakeholder interests.

CK Life Sciences Secures Strong Shareholder Support at AGM

CK Life Sciences International (Holdings) Inc. successfully conducted its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed with overwhelming support. The resolutions included the approval of the audited financial statements for 2024, the election of directors, the appointment of auditors, and the granting of mandates to issue and buy back shares. This outcome reinforces the company’s governance structure and operational strategy, potentially strengthening its market position and shareholder confidence.

CK Life Sciences Enhances Governance with Updated Nomination Committee Terms

CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Nomination Committee, which was established to ensure effective corporate governance in compliance with the Hong Kong Stock Exchange’s Listing Rules. The committee is responsible for reviewing the board’s structure and composition, identifying and recommending director candidates, assessing director independence, and supporting board performance evaluations. These measures are designed to align the board’s capabilities with the company’s strategic goals and enhance shareholder value.

CK Life Sciences Strengthens Governance with New Audit Committee Terms

CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Audit Committee, which plays a crucial role in overseeing the company’s financial reporting, risk management, and internal control systems. The Audit Committee is composed of non-executive directors, with a majority being independent, and is tasked with ensuring compliance with corporate governance standards. This announcement underscores the company’s commitment to maintaining robust governance practices, which is vital for stakeholder confidence and the company’s operational integrity.